Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Medtronic
Mallinckrodt
McKinsey
AstraZeneca

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Upadacitinib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for upadacitinib and what is the scope of patent protection?

Upadacitinib is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for upadacitinib
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 24
Clinical Trials: 20
Patent Applications: 30
DailyMed Link:upadacitinib at DailyMed
Recent Clinical Trials for upadacitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 1
AbbViePhase 2
AbbViePhase 3

See all upadacitinib clinical trials

Synonyms for upadacitinib
(3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide
(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-
1310726-59-0
1310726-60-3
4RA0KN46E0
ABT 494
ABT-494
ABT-494 enantiomer
ABT494
AC-30326
BCP19011
CHEMBL3622821
CS-6150
D10994
EX-A1628
GTPL9246
HY-19569
J3.590.729G
MFCD30502663
Rinvoq
SB19218
SCHEMBL9991056
UNII-4RA0KN46E0
Upadacitinib (USAN/INN)
Upadacitinib [USAN:INN]
Upadacitinib, ABT-494

US Patents and Regulatory Information for upadacitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-001 Aug 16, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKesson
Mallinckrodt
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.